Radiopharm's RAD101 Trial Ignites 153% Surge: Is This the Catalyst for a Biotech Breakout?

Summary
• Radiopharm Theranostics (RADX) surges 153.52% intraday, trading at $10.80 after opening at $13.91
• Interim Phase 2b trial shows 92% MRI concordance for RAD101 in brain metastases imaging
• FDA Fast Track Designation and $500M+ U.S. market potential highlighted in investor webinar

Radiopharm Theranostics (RADX) has ignited a historic intraday rally, surging 153.52% to $10.80 as interim Phase 2b trial results for RAD101 revealed 92% MRI concordance in brain metastases imaging. The stock’s volatile trajectory—from a high of $16.25 to a low of $10.10—reflects both institutional optimism and retail frenzy. With FDA Fast Track Designation and a $500M+ market opportunity, the company’s upcoming webinar on Dec 15–16 could crystallize momentum or trigger profit-taking.

92% MRI Concordance and FDA Fast Track Fuel Radiopharm's Volatility
Radiopharm’s 153.52% intraday surge stems from groundbreaking interim data showing 92% concordance between RAD101 PET imaging and MRI in 12 of 13 patients with brain metastases. This achievement, coupled with FDA Fast Track Designation for distinguishing recurrent disease from treatment effects, has redefined the stock’s risk-reward profile. The 50% enrollment milestone in the Phase 2b trial and $500M+ U.S. market potential cited by management further amplify investor sentiment. However, the stock’s 281.29% turnover rate and 52-week high of $16.25 suggest aggressive short-term positioning, with volatility likely to persist ahead of the Dec 16 webinar.

Biotech Sector Mixed as Radiopharm Outpaces Peers
While the broader biotech sector remains range-bound, Radiopharm’s 153.52% intraday surge dwarfs Amgen’s (AMGN) 1.14% gain. The sector’s focus on late-stage trials and regulatory milestones contrasts with Radiopharm’s singular catalyst-driven rally. However, the stock’s -3.51 P/E ratio and -953.51 operating margin highlight structural risks absent in more diversified biotech leaders.

Navigating RADX’s Volatility: ETFs, Technicals, and Options Playbook
• RSI (14): 42.25 (oversold territory)
• MACD: -0.218 (bearish signal), Histogram: 0.018 (divergence)
• Bollinger Bands: Wide range (4.14–4.80), indicating high volatility
• 200-Day MA: $5.09 (current price at 208% discount)
• Support/Resistance: 4.14–4.22 (200D), 4.23–4.25 (30D)

RADX’s technical profile suggests a continuation of short-term volatility amid a long-term ranging pattern. The RSI’s approach to oversold levels and MACD divergence hint at potential short-term rebounds, but the stock’s -3.51 P/E and -953.51 operating margin underscore fundamental risks. With no options chain provided, leveraged ETFs remain absent, but traders should monitor the 4.14–4.22 support zone and 4.80 upper Bollinger Band as critical levels. The Dec 16 webinar could act as a catalyst for a breakout or breakdown.

Backtest Radiopharm Stock Performance
The backtest of RADX's performance after a 154% intraday surge from 2022 to now reveals mixed results. While the ETF experienced a maximum return of 3.92% on December 58, 2025, the overall trend was negative, with a -1.74% return over the 3 days and a -1.60% return over the 10 days following the surge. The 30-day return was slightly positive at -0.19%, but the win rates for both 3-day and 10-day periods were below 50%, indicating that the ETF was more likely to experience a decline than a gain in the short term following the intraday surge.

RADX at Inflection Point: Webinar to Define Next Move
Radiopharm’s 153.52% intraday surge underscores the transformative potential of RAD101 in brain metastases imaging, but sustainability hinges on the Dec 16 webinar and Phase 2b trial validation. Technical indicators suggest a volatile near-term path, with key support at 4.14 and resistance at 4.80. Investors should watch Amgen’s (AMGN) 1.14% gain as a sector benchmark while prioritizing risk management. For aggressive bulls, a post-webinar breakout above 4.80 could reignite momentum, but a breakdown below 4.14 would signal renewed bearishness. Act now: Secure stop-loss orders below 4.22 and prepare for webinar-driven volatility.